iSpecimen (ISPC)
Order-driven marketplace for annotated human biospecimens.
Something off on this page? Send us feedback.
Connects life-science researchers with annotated human biofluids, tissue, and cells through an order-driven procurement marketplace, earning transactional per-specimen or project revenue and sharing proceeds with providers. It harmonizes de-identified data and coordinates search, compliance, and fulfillment instead of maintaining a large proprietary biobank.
Matches life-science researchers with annotated human biofluids, solid tissue, and hematopoietic stem and immune cells through an order-driven procurement marketplace. Customers pay per specimen or project, while supplying healthcare organizations and commercial providers receive a share of revenue. The offer spans remnant and consented research-use-only samples, banked inventory, prospective custom collections, clinical annotation, and matched sets.
Rather than maintaining a large proprietary biobank, the company harmonizes de-identified records from provider systems and coordinates cohort search, contracting, compliance, ordering, fulfillment, and supplier revenue sharing. Its network extends across the Americas, Europe, and Asia, but customer demand is centered in the Americas and fulfillment depends on suppliers meeting precise specimen criteria.
Operations rely on privacy, human-subject, consent, shipping, import/export, and cross-border data-transfer requirements. The marketplace migration remains incomplete: some product lines still lack full self-service patient-level search and pricing functionality.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $240.9K · Total assets $7.4M · Shareholders' equity $1.7M
- Revenue
- $151.9K
- Operating income
- −$1.4M
- Net income
- −$1.4M
No dividends on record.
| Institutions | 0.00% | 0 shares | |
|---|---|---|---|
| 1 holder · as of Mar 31, 2026 | |||
| Other | 100.00% | 138.9K shares | |
| remainder | |||
138.9K company shares as of Sep 6, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.52M in the company's Sep 22, 2026 report, 138.9K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gill Capital Partners, LLCInstitution | 0.00% | 15 | as of Mar 31, 2026 |
Empery Asset Management, LPInstitution | —5.34% of class, as filed | — | filed Jan 24, 2022 |
James G. WolfInsider | —6.13% of class, as filed | — | filed Sep 28, 2022 |
Andrew L. Ross1Insiderdirector | 1.19% | 1,658 | filed May 17, 2023 |
OBF Investments, LLC2,3Strategic10 percent owner | 0.76% | 1,052 | filed Jun 23, 2021 |
- Last filed May 17, 2023; leaving the company requires no filing. Not in the bar.
- Last filed Jun 23, 2021; leaving the company requires no filing. Not in the bar.
- Reported at 4.40% on Feb 14, 2025, under the 5% line, so no further filing is required.
Insider tradesForm 4
Nothing filed in the last 12 months.
- Quest Diagnostics
Remnant-sample access and custom collections for life-science studies.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| iSpecimen | $1.25 | −1.07% | $183.3K | — | — | 0.4 | −78.7% |
| Quest Diagnostics | $234.76 | −0.04% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Median | 26.0 | 20.5 | 2.3 | +10.2% |